Invesco Pharmaceuticals ETF
PJP
93 hedge funds and large institutions have $64.9M invested in Invesco Pharmaceuticals ETF in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 12 closing their positions.
1.13% more ownership
Funds ownership: 23% → 24.13% (+1.1%)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
2% less capital invested
Capital invested by funds: $66M → $64.9M (-$1.1M)
4% less funds holding
Funds holding: 97 → 93 (-4)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.51M |
| 2 |
Goldman Sachs
New York
|
+$2.75M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$790K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$697K |
| 5 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$508K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$2.41M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.19M |
| 3 |
Jane Street
New York
|
-$1.16M |
| 4 |
QAM
Q3 Asset Management
Birmingham,
Michigan
|
-$812K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$680K |
PJP Hedge Fund Activity: Q4 2024 in Review
93 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q4 2024, worth a combined $64.9M — down 1.7% from $66M a quarter earlier.
Fund positioning in PJP was balanced in Q4 2024: 12 funds opened new positions, 12 closed out, 18 added to existing stakes and 24 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.51M. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $2.41M.
- 93 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q4 2024, down from 97 in Q3 2024.
- Funds reported $64.9M of Invesco Pharmaceuticals ETF stock for Q4 2024, down 1.7% quarter-over-quarter.
- 12 funds opened new Invesco Pharmaceuticals ETF positions in Q4 2024 and 12 closed out, a net change of 0 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q4 2024 was Morgan Stanley, an estimated $4.51M added.
- The largest Invesco Pharmaceuticals ETF seller in Q4 2024 was Cambridge Investment Research Advisors, an estimated $2.41M sold.
Based on aggregated 13F filings for Q4 2024.